XML 57 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration, License, Co-Promotion and Other Commercial Agreements - China, Hong Kong and Macau (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 31, 2014
Oct. 31, 2012
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Collaboration, License and Co-Promotion Agreements            
Collaborative arrangements revenue     $ 64,612 $ 54,350 $ 116,489 $ 120,392
Linaclotide            
Collaboration, License and Co-Promotion Agreements            
Collaborative arrangements revenue         200  
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau            
Collaboration, License and Co-Promotion Agreements            
Prior notice period to terminate the agreement   180 days        
Up-front fee received   $ 25,000        
Additional budget for activities supporting the development of linaclotide $ 14,000          
Total amount of non-contingent arrangement consideration   34,000        
Amount of arrangement consideration for clinical trial material supply services and research, development and regulatory activities   $ 9,000        
Percentage of costs of clinical trial material supply services and research, development and regulatory activities allocated   55.00%        
Arrangement Consideration allocated to the License Deliverable   $ 29,700        
Arrangement Consideration allocated to the R&D Services   1,800        
Arrangement Consideration allocated to the JDC services   100        
Arrangement Consideration allocated to the clinical trial material supply services   300        
Arrangement Consideration allocated to Co-Promotion Deliverable   2,100        
Net cost sharing offset or incremental expense related to research and development expense     $ 200 200 200 200
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau | Linaclotide            
Collaboration, License and Co-Promotion Agreements            
Collaborative arrangements revenue       164 $ 208 294
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau | Sales milestones            
Collaboration, License and Co-Promotion Agreements            
Milestone payment to be received by company upon milestone achievement   $ 125,000        
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau | Commercialization milestone            
Collaboration, License and Co-Promotion Agreements            
Percentage of net profit from commercialization   55.00%        
Percentage of net loss from commercialization   55.00%        
AstraZeneca | Collaborative Arrangement, License Deliverable | China, Hong Kong, and Macau            
Collaboration, License and Co-Promotion Agreements            
Collaborative arrangements revenue       $ 200   $ 300